为期2年的舌下草花粉免疫治疗对中重度季节性过敏性鼻炎患者3年后过敏原激发鼻腔反应的影响:GRASS随机临床试验
GRASS随机双盲安慰剂对照3平行组研究在单一学术中心纳入106例中重度季节性过敏性鼻炎成人患者,比较2年舌下免疫治疗与安慰剂在3年随访时对鼻腔过敏原激发反应的影响。意向治疗人群中,舌下免疫治疗组3年时总鼻症状评分与安慰剂组差异无统计学意义(组间差 -0.18,95%CI -1.25 至 0.90,P = .75)。
要点
- 2年舌下草花粉免疫治疗在3年随访时对鼻腔过敏原激发反应与安慰剂无显著差异。
- 主要结局总鼻症状评分组间差 -0.18(95%CI -1.25 至 0.90;P = .75)。
- 研究未设功效比较舌下与皮下免疫治疗,皮下免疫治疗仅作阳性对照。
核心结论
- 在中重度季节性过敏性鼻炎患者中,2年舌下草花粉免疫治疗在3年随访时改善鼻腔过敏原激发反应方面与安慰剂无显著差异。
研究设计与样本
- 随机双盲、安慰剂对照、3平行组研究,在单一学术中心帝国理工学院伦敦开展。
- 纳入成人中重度季节性过敏性鼻炎患者(干扰日常活动或睡眠),首次入组2011年3月,末次随访2015年2月。
- 36例接受2年舌下免疫治疗(每日含15 µg主要过敏原Phleum p 5的片剂及每月安慰剂注射),36例接受皮下免疫治疗(每月含20 µg Phleum p 5的注射及每日安慰剂片剂),34例接受匹配的双安慰剂。
- 在治疗前、治疗1年和2年以及3年时(治疗停止后1年)进行鼻腔过敏原激发。
- 主要结局为3年时舌下免疫治疗组与安慰剂组总鼻症状评分(TNSS;范围0[最佳]至12[最差])比较,皮下免疫治疗作为阳性对照,研究未设功效比较舌下与皮下免疫治疗。
主要发现
- 106例随机参与者(平均年龄33.5岁;34例女性[32.1%]),92例在3年时完成研究。
- 意向治疗人群中,舌下免疫治疗组平均TNSS评分治疗前为6.36(95%CI 5.76至6.96),3年时为4.73(95%CI 3.97至5.48)。
- 安慰剂组平均TNSS评分治疗前为6.06(95%CI 5.23至6.88),3年时为4.81(95%CI 3.97至5.65)。
- 基线调整后的组间差为 -0.18(95%CI -1.25至0.90;P = .75)。
- TNSS个体内变化的最小临床重要差异为1.08。
关键数值与推荐
- 主要结局为3年时舌下免疫治疗组与安慰剂组总鼻症状评分比较,组间差 -0.18(95%CI -1.25至0.90;P = .75)。
- TNSS范围0(最佳)至12(最差),个体内变化的最小临床重要差异为1.08。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究未设功效比较舌下免疫治疗与皮下免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal allergic rhinitis. Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy has been shown to improve symptoms for at least 2 years following discontinuation of treatment. OBJECTIVE: To assess whether 2 years of treatment with grass pollen sublingual immunotherapy, compared with placebo, provides improved nasal response to allergen challenge at 3-year follow-up. DESIGN, SETTING, AND PARTICIPANTS: A randomized double-blind, placebo-controlled, 3-parallel-group study performed in a single academic center, Imperial College London, of adult patients with moderate to severe seasonal allergic rhinitis (interfering with usual daily activities or sleep). First enrollment was March 2011, last follow-up was February 2015. INTERVENTIONS: Thirty-six participants received 2 years of sublingual immunotherapy (daily tablets containing 15 µg of major allergen Phleum p 5 and monthly placebo injections), 36 received subcutaneous immunotherapy (monthly injections containing 20 µg of Phleum p 5 and daily placebo tablets) and 34 received matched double-placebo. Nasal allergen challenge was performed before treatment, at 1 and 2 years of treatment, and at 3 years (1 year after treatment discontinuation). MAIN OUTCOMES AND MEASURES: Total nasal symptom scores (TNSS; range; 0 [best] to 12 [worst]) were recorded between 0 and 10 hours after challenge. The minimum clinically important difference for change in TNSS within an individual is 1.08. The primary outcome was TNSS comparing sublingual immunotherapy vs placebo at year 3. Subcutaneous immunotherapy was included as a positive control. The study was not powered to compare sublingual immunotherapy with subcutaneous immunotherapy. RESULTS: Among 106 randomized participants (mean age, 33.5 years; 34 women [32.1%]), 92 completed the study at 3 years. In the intent-to-treat population, mean TNSS score for the sublingual immunotherapy group was 6.36 (95% CI, 5.76 to 6.96) at pretreatment and 4.73 (95% CI, 3.97 to 5.48) at 3 years, and for the placebo group, the score was 6.06 (95% CI, 5.23 to 6.88) at pretreatment and 4.81 (95% CI, 3.97 to 5.65) at 3 years. The between-group difference (adjusted for baseline) was -0.18 (95% CI, -1.25 to 0.90; [P = .75]). CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe seasonal allergic rhinitis, 2 years of sublingual grass pollen immunotherapy was not significantly different from placebo in improving the nasal response to allergen challenge at 3-year follow-up. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01335139; EudraCT Number: 2010-023536-16.
引用
- Scadding GW, Calderon MA, Shamji MH, et al. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial. JAMA. 2017. PMID: 28196255. doi:10.1001/jama.2016.21040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。